Senda Biosciences is a therapeutics platform that utilizes Endless RNA™ technology and proprietary programmable nanoparticles to create programmable medicines capable of expressing diverse proteins within the body. This approach aims to enhance the therapeutic potential of RNA for treating various diseases, including oncology and rare conditions, by providing long-lasting and targeted treatment options.
Funding
Funding not disclosed
BMFounders
Product
Problem
Current RNA therapies face challenges in achieving sustained protein expression and targeted delivery to specific tissues, limiting their effectiveness in treating chronic diseases and requiring frequent administration. Existing delivery methods often lack the precision needed to minimize off-target effects and maximize therapeutic impact.
Solution
Senda Biosciences is developing a programmable medicine platform that combines Endless RNA (eRNA) technology with proprietary programmable nanoparticles to enable sustained protein expression and targeted delivery. The eRNA is a class of synthetic, translatable, and stable RNA that can be programmed to express diverse proteins inside the body for extended periods. The Natural NanoParticles (NNPs) are derived from natural sources and designed with a chemical "routing code" to shuttle biomolecules into human cells with unique tropism and the ability to be re-dosed. The platform leverages AI algorithms and rapid prototyping to design RNA medicines with enhanced performance and broad applicability.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing novel RNA-based therapeutics for oncology, metabolic disorders, infectious diseases, rare diseases, and immunology.
Features
- Endless RNA (eRNA) technology for sustained and programmable protein expression.
- Natural NanoParticles (NNPs) for targeted delivery to specific tissues and cells.
- Proprietary chemical "routing code" for precise nanoparticle trafficking.
- AI-driven design for optimizing RNA medicine performance.
- Rapid prototyping and testing bioplatform for accelerated development.
- Potential for various routes of administration, including re-dosing.
- Applicability to oncology, metabolic disease, infectious diseases, rare diseases, and immunology.